Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.54 |
| ▸ | RELA | Q04206 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.46 |
| ▸ | COMT | P21964 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 3/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10091200 | 0.85 | NPC1 (0.67) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL436106 | 0.85 | NPC1 (0.65) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL16727393 | 0.83 | RAB9A (0.55) | NPC1RAB9ASMN1; SMN2HDAC4 | |
| SCHEMBL10128364 | 0.82 | RAB9A (0.57) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL17055377 | 0.81 | NPC1 (0.67) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL10128407 | 0.79 | RAB9A (0.48) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL19940390 | 0.79 | NPC1 (0.48) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL9697154 | 0.79 | CLK4 (0.53) | NPC1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL2616114 | 0.78 | IDO1 (0.47) | NPC1RAB9ASMN1; SMN2HDAC4 | |
| SCHEMBL12441012 | 0.78 | ALDH1A1 (0.48) | NPC1NFKB1RAB9ANFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10400001-B2 | Heteroleptic iridium complex, and light-emitting material and organic light-emitting element using compound | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2019-09-03 | — | — | US | disclosed |
| US-20180066001-A1 | HETEROLEPTIC IRIDIUM COMPLEX, AND LIGHT-EMITTING MATERIAL AND ORGANIC LIGHT-EMITTING ELEMENT USING COMPOUND | FURUYA METAL CO., LTD. (JP) | 2018-03-08 | — | — | US | disclosed |
| US-20180066001-A1 | HETEROLEPTIC IRIDIUM COMPLEX, AND LIGHT-EMITTING MATERIAL AND ORGANIC LIGHT-EMITTING ELEMENT USING COMPOUND | FURUYA METAL CO., LTD. (JP) | 2018-03-08 | — | — | US | disclosed |
| US-8993754-B2 | Iridium complex and light emitting material formed from same | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2015-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10400001-B2 | Heteroleptic iridium complex, and light-emitting material and organic light-emitting element using compound | INTS9, RPL19, RPL29 | NPC1 2580/4885NFKB1 2348/4885RAB9A 1508/4885 |
| US-20180066001-A1 | HETEROLEPTIC IRIDIUM COMPLEX, AND LIGHT-EMITTING MATERIAL AND ORGANIC LIGHT-EMITTING ELEMENT USING COMPOUND | INTS9, RPL19, RPL29 | NPC1 2580/4885NFKB1 2348/4885RAB9A 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.